Letter to the Editor: Using Randomized Controlled Trials to Evaluate the Effectiveness of Subcutaneous Furosemide in Advanced Heart Failure Patients With Palliative Care Needs
Restricted accessLetterFirst published online August, 2023
Letter to the Editor: Using Randomized Controlled Trials to Evaluate the Effectiveness of Subcutaneous Furosemide in Advanced Heart Failure Patients With Palliative Care Needs
O'LearyN. The comparative palliative care needs of those with heart failure and cancer patients. Curr Opin Support Palliat Care, 2009; 3:241–246; doi: 10.1097/SPC.0b013e328332e808
2.
AlexH, AdejokeOO, NatalieB, et al.Advanced heart failure: parenteral diuretics for breathlessness and peripheral oedema—Systematic review. BMJ Support Palliat Care, 2022:spcare-2022-003863; doi: 10.1136/spcare-2022-003863
3.
SicaDA, MuntendamP, MyersRL, et al.Subcutaneous furosemide in heart failure: Pharmacokinetic characteristics of a newly buffered solution. JACC Basic Transl Sci, 2018; 3:25–34; doi: 10.1016/j.jacbts.2017.10.001
4.
ClinicalTrials.gov. Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study (SUBQ-HF) NCT03170219. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03170219 [Last accessed: October29, 2021].
